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A B S T R A C T
Our animal and human studies have provided empirical evidence that a patented
intranasal herbal medicine alters brain functions and neurophysiology. In particular, it
reduces clinical symptoms and immunological anomalies in children with autism
spectrum disorders (ASD). The present study explored whether the herbal formula can
improve executive functions and the associated neuroelectrophysiological activity in ASD.
Thirty children with ASD were evenly assigned to receive a daily intranasal administration
of the herbal formula or no treatment. Their executive functions, behavioral problems, and
electroencephalographic activity during an executive control task were measured before
and after six months of treatment with the herbal formula. After treatment, the
experimental group showed signiﬁcantly improved inhibitory control, mental ﬂexibility,
and planning, which coincided with an event-related elevation in the activity of their
prefrontal and anterior cingulate cortices (regions that are critical for executive control of
behaviors) as well as reduced daily dysexecutive behaviors. In contrast, the control group
showed no signiﬁcant changes in executive functions or neural system activity. These
ﬁndings support the administration of the intranasal herbal medicine as a possible
intervention for improving executive functions in ASD.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Executive dysfunction refers to difﬁculties in response inhibition, mental ﬂexibility, self-monitoring, planning, and/or
working memory. Such cognitive deﬁcits are common in people with autism spectrum disorders (ASD) (Kenworthy, Yerys,
Anthony, & Wallace, 2008; Sanders, Johnson, Garavan, Gill, & Gallagher, 2008). Executive dysfunction is suggested to be
accounted for the typical clinical manifestations of ASD, including uncontrollable behavioral and emotional reactions,
repetitive behavior, strong need for sameness, restricted interests, and inappropriate social communication and interaction.* Corresponding author at: Department of Psychology, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong Special Administrative Region.
Tel.: +852 3943 6654; fax: +852 2603 5019.
E-mail addresses: aschan@psy.cuhk.edu.hk (A.S. Chan), lmsze@psy.cuhk.edu.hk (S.L. Sze), ymyhan@ied.edu.hk (Yvonne M.Y. Han).
http://dx.doi.org/10.1016/j.rasd.2014.03.007
1750-9467/ 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
3.0/).
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on everyday functioning, independent living, and care giving in individuals with ASD.
In view of the pervasive impact of executive dysfunctions in ASD, a growing number of studies have investigated potential
interventions for enhancing executive functions in ASD. The majority of interventions have been behavior-based (Goin-
Kochel, Myers, & Mackintosh, 2007; National Research Council, 2001). Some of these interventions showed positive
outcomes but may be relatively intensive and time-consuming (Ospina et al., 2008; Vismara & Rogers, 2010). Furthermore,
some of the methods may be hardly applicable or less effective for individuals with limited intellectual functioning or severe
autistic symptoms (Kenworthy et al., 2013; Matson & Smith, 2008). Thus, for many of those cases, especially when
uncontrollable emotions or behaviors and severe inattention are involved, pharmacological interventions are considered for
their beneﬁcial effects on stabilizing mood and improving attention and behavioral problems (Huffman, Sutcliffe, Tanner, &
Feldman, 2011). One study estimated that psychotropic drugs were prescribed to approximately 30% of the ASD cohort, and
polypharmacy was observed in one-third of the prescribed individuals (Murray et al., 2013). However, there is still no
standard medication guideline for treating ASD, and some individuals are refractory to drug treatment or may have difﬁculty
tolerating or communicating about the side effects of medication (Aman, Van Bourgondien, Osborne, & Sarphare, 1997;
Frazier et al., 2011).
While pharmacological treatments are predominantly administered peripherally (e.g., oral administration), there is a
growing trend in research of exploring the applicability of intranasal drug delivery to treat central nervous system (CNS)
dysfunction. Intranasal treatment, which is a non-invasive means of administration, not only allows drugs to bypass the
blood-brain barrier but may also increase the bioavailability of the active drug that reaches the brain compared to oral
administration (Chapman et al., 2013). Empirical evidence supports the effectiveness of intranasal administration for the
treatment of various brain disorders, including benzodiazepines for epilepsy (Fis¸ gin et al., 2002; Holsti et al., 2010), stem
cells for Parkinson’s disease (Bossolasco et al., 2012; Danielyan et al., 2011), and insulin for dementia of the Alzheimer’s type
(Craft et al., 2012; Schio¨th, Frey, Brooks, & Benedict, 2012). Recently, a handful of studies have investigated the effectiveness
of the intranasal administration of oxytocin to individuals with ASD in reducing repetitive behaviors, increasing social
behaviors and emotion processing, and modulating the brain activity involved in face processing. Although some positive
results have been reported (Andari et al., 2010; Domes et al., 2013; Guastella et al., 2010; Hollander et al., 2003, 2007), some
studies with larger sample sizes and repeated intranasal administrations failed to ﬁnd any signiﬁcant difference between
oxytocin and placebo (Anagnostou et al., 2012; Dadds et al., 2013).
Despite the inconclusive ﬁndings on oxytocin, the intranasal administration method is considered safe and effective
(Chapman et al., 2013; Djupesland, 2013; Illum, 2003), and our laboratory has thus studied this delivery route, using an
herbal formula as an intervention, to improve brain function. This formula, using natural borneol as one of the active
ingredients, was recently patented as a formula for improving brain function and an intervention for brain disorders (patent
number ZL 2008 1 0176088.7). In Traditional Chinese Medicine, borneol is a well-known substance for improving the mind
and thoughts because of its capacities to direct drugs upward to the head, targeting the brain (Liu, Liang, Chen, Feng, & Zhao,
1994), to facilitate the permeation of drugs across the blood–brain barrier, and to enhance drug distribution in brain tissue
(Chen et al., 2010; Yu et al., 2011; Yu, Ruan, Dong, Yu, & Cheng, 2013). In our patent application, we reported that mice
receiving seven days of the herbal formula had higher levels (p < 0.001) of norepinephrine in the brain (mean: 46.10 pg/mg
of tissue) compared to those receiving saline solution (mean: 22.03 pg/mg of tissue); the mice that received three days of the
herbal formula also had higher levels of norepinephrine in the brain (mean: approximately 33 pg/mg of tissue) than did
those receiving saline solution (p < 0.001). In sum, the preliminary data suggests that borneol may be an effective agent to
improve brain activities.
Additional pilot data from human studies substantiated the effects of the herbal medicine on mice. An experiment on 14
adults with a counterbalanced design showed that the intranasal administration of the herbal formula elicited a signiﬁcant
elevation of electroencephalographic (EEG) activity in the anterior cingulate cortex (ACC) that was localized by low-
resolution brain electromagnetic tomography analyses (LORETA), whereas the administration of the saline solution did not
result in any change in brain activity (Chan, Cheung, Sze, Leung, & Shi, 2011a). In another double-blinded pilot study, twelve
children with ASD were randomly assigned to receive daily intranasal application of the herbal formula or the saline solution
for one month. Parents of the children who received the herbal nasal drops reported greater improvement in spontaneous
speech output, inhibition of repetitive speech, and initiation of behavior than did the parents whose children applied the
saline solution (data published in Chan et al., 2011a). Further empirical support for the therapeutic effect of the herbal nasal
drops over a longer term (i.e., for six months) has been indicated in a recent controlled study on children with ASD. Based on
parental ratings, signiﬁcant improvement in social functioning and self-control were found in children given the intranasal
treatment but not in the no-treatment control group (data submitted for publication). Interestingly, their reduced problem
behaviors were correlated with their altered peripheral blood concentration of speciﬁc T lymphocyte subsets, which has
been postulated to be a biomarker of the neuropathogenesis of autism and associated with core autistic symptoms (Goines &
Van de Water, 2010; Han, Leung, Wong, Lam, Cheung, & Chan, 2011; Han et al., 2013).
Given the emerging evidence for the effectiveness of the herbal nasal drops, the present study aimed to examine the
herbal formula as a potential intervention for enhancing executive functions and the associated neuro-electrophysiology of
children with ASD. It is anticipated that children in the experimental group will demonstrate a greater improvement in the
executive functions that are commonly deﬁcient in ASD, including self-control, ﬂexible thinking, and planning, compared to
the control group. Such a treatment-induced improvement in the executive functions is expected to be found in both
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electrophysiological studies have revealed that a distributed neural network involving the inferior frontal cortex (IFC; BA10/
47), dorsolateral prefrontal cortex (DLPFC; BA9/46), pre-supplementary motor area (pSMA; BA6), and ACC (BA24/32) plays a
crucial role in mediating the executive control of behavior involving response selection, inhibition, and monitoring
(Chambers, Garavan, & Bellgrove, 2009; Kiesel et al., 2010). Cumulative research ﬁndings suggest that children and adults
with ASD have reduced functional activity in the IFC, DLPFC and ACC compared with normal counterparts, which is
associated with the executive control deﬁcits in ASD (Chan et al., 2011d; Kana, Keller, Minshew, & Just, 2007; Philip et al.,
2012). Therefore, it is also anticipated that the enhanced executive functions in the experimental group in the present study
will be in line with elevated neuro-electrophysiological activity in the prefrontal (PFC) and anterior cingulate cortices during
an executive control task as measured using a source localization method (i.e., standardized low-resolution brain
electromagnetic tomography analyses, sLORETA).
2. Methods
2.1. Ethics and consent
The study was conducted in accordance with the Helsinki Declaration of the World Medical Association Assembly. The
research protocol was approved by the Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research
Ethics Committee (CREC Ref. No.: CRE-2008.421-T) and the Chinese Clinical Trial Registry (Registration No.: ChiCTR-TRC-
12001857). Prior to the study, all children and their parents were briefed on the procedure of the study, and written informed
consent was obtained from the parent of each participant.
2.2. Participants
Forty-eight children with ASD, aged between 7 and 17 years old, voluntarily participated in the study. They were
recruited from the database of the Neuropsychology Laboratory of the Chinese University of Hong Kong and from two local
schools in Hong Kong, through email invitation and a brieﬁng talk conducted at the schools. A clinical psychologist who was
blind to the study rationale and group assignment conducted a structured clinical interview of the parents on the
developmental and medical history and current functioning of the children; this interview was based on the DSM-IV-TR
(American Psychiatric Association, 2000) and the Autism Diagnostic Interview-Revised (ADI-R) (Lord, Rutter, & Couteur,
1994). All but six of the children met the DSM-IV-TR and ADI-R diagnostic criteria of Autistic Disorder, Asperger’s Disorder, or
Pervasive Developmental Disorder, Not Otherwise Speciﬁed. Six children declined to participate or dropped out due to
personal reasons, and six children either with other neurodevelopmental, psychiatric or neurological comorbidities or who
had been prescribed psychiatric medication were excluded from the study.
Among the remaining 30 children, 15 children received the six-month intranasal application of the herbal formula and
served as the experimental group, while the other 15 children did not receive the treatment and served as the control group.
Table 1 shows that the children in the two groups were matched for age, t(28) = 0.29, p = 0.77, gender, x2(1) = 0.24, p = 0.62,
and severity of autistic symptoms as measured by the three ADI-R subscales, with t ranging from 1.43 to 0.74, and p ranging
from 0.17 to 0.47. The two groups also demonstrated comparable levels of general intelligence, t(28) = 0.10, p = 0.92.
2.3. Procedures
After obtaining consent from all participants, the baseline assessment was conducted individually on the children and
their parents. Trained research assistants assessed the children’s intellectual functioning, executive functions, and EEG
activities. During the EEG recording, each child was required to perform a Go/No-Go task while their EEG data were obtainedTable 1
Baseline demographic and clinical characteristics of participants in the control and experimental groups.
Characteristics Control group (n = 15) Experimental group (n = 15) t/x2 P value
Age (mean  SD), years 11.60  2.64 11.88  2.70 0.29 0.77
Gender-Male (%) 80.0 86.7 0.24 0.62
IQ (mean  SD) 85.25  15.98 84.53  23.60 0.10 0.92
Diagnosis 2.69 0.26
Autistic disorder (%) 66.7 40.0
PDD-NOS (%) 33.3 53.3
Asperger’s disorder (%) 0 6.7
Severity of disorder (mean  SD)
ADI-R Social Interaction 19.20  6.73 21.07  7.15 0.74 0.47
ADI-R Communication 14.20  4.30 11.93  4.42 1.43 0.17
ADI-R Stereotyped Behavior 4.73  2.81 3.93  2.91 0.77 0.45
Notes. ADI-R: Autism Diagnostic Interview-Revised; IQ: intelligence quotient as assessed by the Chinese version of Wechsler Intelligence Scale for Children
Third Edition or the Stanford-Binet Intelligence Scale-Fourth Edition; PDD–NOS: Pervasive Developmental Disorders, Not Otherwise Speciﬁed.-
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(Klem, Lu¨ders, Jasper, & Elger, 1999). With electrode impedances maintained at 10 kV, the EEG signals were referenced to
linked ears at a 256 sampling rate, with a high-frequency limit band pass of 30 Hz. Meanwhile, their parents were
interviewed by a clinical psychologist about the children’s developmental and medical history using a structured clinical
interview, and by a trained research assistant about their children’s daily behavioral problems related to executive
dysfunction using three standardized questionnaires. The clinical psychologist and research assistants who conducted the
assessments were blinded to the rationale of the study and the group assignment.
Following the baseline assessments, the children in the experimental group were instructed to apply the herbal nasal
drops at a dose of 10 ml per day, whereas those in the control group did not receive any treatment. After the six-month
treatment, the same set of assessments was performed on the children and their parents individually.
2.4. Herbal nasal drops
The patented herbal nasal drops (patent number ZL 2008 1 0176088.7) were manufactured by the Hong Kong Institute of
Biotechnology Limited, which is wholly controlled by the council of the Chinese University of Hong Kong. The product was
manufactured under strict Good Manufacturing Practice (GMP) standards. The product has been tested for heavy metal and
toxic elements, microbial examination and pesticides residue. The test results met the product safety guidelines set forth by
the Department of Health of the Government of Hong Kong. Its major active ingredients include Borneol and Borax (please
refer to the patent record for details). All ingredients in the formula are within the allowed daily dosage as prescribed in the
Chinese Herbal Medicine published by the Educational Board of the National Drug Administration. Blood samples were
collected from each participant in the experimental group at the end of the ﬁrst and sixth months of intervention to test their
liver function and monitor any possible side-effects of the herbal nasal drop. The results of the blood assays indicated that all
liver function indices were within normal limits
2.5. Measures
2.5.1. Neuropsychological assessments on executive functions
2.5.1.1. The d2 test of attention (d2) (Brickenkamp & Zillmer, 1998). d2 requires the accurate and speedy cancelation of ‘d’s
with two dashes in an array of 14 rows of target and non-target (e.g., ‘d’s without two dashes or ‘p’s) stimuli. A higher
concentration performance score and lower total commission errors (i.e., cancelation of non-target stimuli) indicate better
response selection and inhibitory control.
2.5.1.2. The second trial of the Children’s Color Trails Test (CCTT) (Williams et al., 1995). CCTT requires ﬂexibly shifting between
colors while connecting numbers from 1 to 15 in ascending order. A shorter completion time and fewer errors (i.e., wrong
connection of number or color) indicate more ﬂexible thinking.
2.5.1.3. The Tower of California Test (ToC) (Delis, Kaplan, & Kramer, 1997). ToC requires planning and formulating efﬁcient
strategies to move discs among three vertical pegs to match a target arrangement without rule violation (i.e., no more than
one disc can be moved at a time and a larger disc cannot be placed on top of a smaller disc). A higher total achievement score
indicates better planning and problem-solving. A lower rule violation ratio (total number of rule violations/total number of
items attempted) reﬂects better inhibitory control.
2.5.2. Parental evaluation of behavioral measures
2.5.2.1. Behavior Rating Inventory of Executive Function (BRIEF) (Gioia, Isquith, Guy, & Kenworthy, 2000). BRIEF requires
parents to rate how often (i.e., ‘‘never’’, ‘‘sometimes’’ or ‘‘often’’) their child exhibits dysexecutive behaviors that cause
difﬁculty in daily functioning. The Global Executive Composite was computed as an overall measure of executive functions,
with higher scores indicating poorer executive functioning. The Metacognition Index was adopted to reﬂect the ability to
plan and organize materials, as well as working memory and problem-solving. Additionally, the Behavioral Regulation Index
was adopted to measure the ability to control emotions and behaviors and to shift the mental set.
2.5.2.2. Hyperactivity Subscales of the Children’s Psychiatric Rating Scale (CPRS) (Fish, 1985) and Conners’ Rating Scales-Revised
(CRS-R) (Conners, 1997). These scales measure the degree of inhibitory control over behavior and emotion. The CPRS rates
four self-control aspects on a scale from 0 to 6, and the CRS-R rates 10 disinhibition-related items on a scale from 0 to 3. The
total subscale scores were computed separately for comparison, with higher scores indicating poorer inhibitory control.
2.5.3. Event-related EEG assessment
The event-related EEG signals from each child were collected while they were performing the Go/No-Go task, a
computerized executive control test that measures the ability to ﬂexibly select and execute appropriate response to
changing stimuli and to inhibit unwanted responses. Details of the Go/No-Go task have been described in two previous
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extracted for analysis using MatLab 7.1, because this condition entails both the executive control processes of selecting to
withhold a response and the process of actually inhibiting a response. The epoch limit was set as 50 ms at the start and
900 ms at the end. Artifacts in the epoched data were then pruned by visual inspection and using the rejection method on the
EEG Plot. The selected data were exported and then spectrally processed via fast Fourier transformation to compute
the power data for the theta (4–7.5 Hz) frequency band using the NeuroGuide software. The theta band was selected because
the ACC (one of our ROIs) is a major source generator of neural activity in the theta band (Asada, Fukuda, Tsunoda,
Yamaguchi, & Tonoike, 1999) and because brain oscillation at this bandwidth has repeatedly been associated with attention
and inhibitory control processes (Chan et al., 2011d; Hermens et al., 2005).
The selected fast Fourier transformed data were analyzed using sLORETA. The sLORETA method is a properly
standardized inverse solution that solves the problem of computing the three-dimensional cortical distribution of the
electric neuronal source activity from the scalp-EEG measurements to yield images of standardized current density with
exact and zero-error localization (Pascual-Marqui, 2002). The sLORETA solution space consists of 6239 voxels (voxel
size: 5 mm  5 mm  5 mm) and is restricted to cortical gray matter and the hippocampi, as deﬁned by the digitized
Montreal Neurological Institute (MNI) 152 template (Fuchs, Kastner, Wagner, Hawes, & Ebersole, 2002). Scalp electrode
coordinates on the MNI brain are derived from the international 5% system (Jurcak, Tsuzuki, & Dan, 2007). A number of
recent studies have validated the reliability of sLORETA and its applicability and sensitivity in experimental and clinical
research (De Ridder, Vanneste, Kovacs, Sunaert, & Dom, 2011; Dumpelmann, Ball, & Schulze-Bonhage, 2012). In the
present study, sLORETA was used to localize the source of scalp-EEG activity in terms of the current density in the ROIs,
including the IFC (BA10/47), DLPFC (BA9/46), pSMA (BA6), and ACC (BA24/32) during the No-Go condition, and the
built-in paired t statistics were used to compare the pre-post difference in current density in the ROIs for each group of
participants.
2.6. Data analyses
Repeated measures ANOVA followed by post hoc paired t tests were performed to compare the pre-post scores on various
neuropsychological measures of executive functions and parental ratings of problem behavior for each group of children. The
analyses were conducted using the SPSS software. Given that speciﬁc hypotheses were tested, the one-tailed paired t test
was adopted, and no adjustment to the alpha level was applied to avoid reducing the power of the tests. The effect sizes and
conﬁdence intervals were used to evaluate the extent of pre-post changes for each group. Furthermore, sLORETA analyses
using voxel-by-voxel paired-sample t tests for each group of children were performed to compare the pre-post changes in
theta current density level in the ROIs during the No-Go condition.
3. Results
3.1. Intranasal herbal medicine improved executive functions
The baseline level of executive functioning was comparable between the experimental and control groups, as
measured by the three neuropsychological tests, t range = 1.78 to 2.07, p > 0.05. Repeated measures ANOVAs were
used to compare the pre-post performance between groups, with time (pre vs. post) as the within-subjects factor and
group (control vs. experimental) as the between-subjects factor. A signiﬁcant time by group interaction was found for
most measures; F range = 4.25–8.07, p < 0.05. All tests showed a signiﬁcant main effect of time; F range = 5.07–17.13,
p < 0.05.
The results of the post hoc paired samples t tests showed that the children in the experimental group demonstrated a
signiﬁcant improvement in all three aspects of executive functions, including response selection and inhibition, mental
ﬂexibility, and planning abilities, t range = 5.07 to 2.72, p < 0.05, with medium to large effect sizes from 0.59 to 1.35
(Table 2). These data suggest that after intranasal treatment, children became more ﬂexible in problem solving, more
attentive to relevant information and more capable of withholding inappropriate response. The same analyses were
repeated for a subgroup of low-functioning children (n = 6), revealing signiﬁcant improvements across various executive
function measures, with t ranges from 2.86 to 4.45, p < 0.05, and suggesting that even low-functioning children with ASD
were able to beneﬁt from the herbal treatment.
In contrast, children in the control group showed less improvement. Although the control group demonstrated some
improvement in two test measures (completion time in CCTT and total achievement score in ToC; t = 2.39 and 2.20, effect
size = 0.64 and 0.59, respectively, p < 0.05), the extent of the improvement observed in the experimental group was four
times greater than that observed in the control group (CCTT: 33.24 in the experimental group vs. 7.29 in the control
group; ToC: 4.38 in the experimental group vs. 1.36 in the control group) and the differences were statistically signiﬁcant,
t = 2.06 and 2.18, respectively, p < 0.05.
In summary, the children who received the herbal formula demonstrated signiﬁcant improvements in
inhibitory control, ﬂexibility, and planning compared with their control counterparts. These ﬁndings indicate that
the intranasal application of the herbal formula may have some positive effects on the executive functions of children
with ASD.
Table 2
Mean performance in executive functioning of the control and experimental groups at pre- and post-six-month period.
Control group (n = 15) p Value E.S. C.I. Experimental group (n = 15) p Value E.S. C.I.
Pre Post Pre Post
Response selection and inhibition
d2: concentration
performance
131.07 (45.96) 132.21 (35.77) 0.46 0.02 28.48 to 26.19 96.07 (57.28) 141.14 (63.34) 0.00** 1.35++ 64.29 to 25.86
d2: commission# 9.43 (17.91) 4.43 (5.72) 0.10 0.36 3.12 to 13.12 21.93 (29.87) 7.00 (10.44) 0.01** 0.69+ 2.43 to 27.43
ToC: RVR# 1.01 (0.97) 1.00 (1.09) 0.47 0.02 0.25 to 0.27 0.95 (0.91) 0.37 (0.58) 0.01** 0.85++ 0.08 to 1.44
Mental ﬂexibility
CCTT: error 0.50 (0.76) 0.36 (0.63) 0.27 0.16 0.36 to 0.64 1.93 (2.46) 0.71 (0.91) 0.02* 0.59+ 0.01 to 2.42
CCTT: time
(in seconds)#
52.00 (21.00) 44.71 (20.11) 0.02* 0.64+ 0.70 to 13.87 82.38 (58.73) 49.14 (20.62) 0.01** 0.73+ 6.84 to 59.63
Planning
ToC: TAS 9.00 (4.66) 10.36 (5.43) 0.02* 0.59+ 2.69 to 0.02 9.62 (6.45) 14.00 (5.72) 0.00** 0.95++ 7.17 to 1.60
Note. d2 – the d2 Test of Attention; CCTT: error – total errors in Trial 2 of the Children’s Color Trails Test; CCTT: time – total completion time in Trial 2 of the
CCTT; ToC: RVR – rule violation ratio of the Tower of California Test; ToC: TAS – total achievement score of the ToC. E.S. – effect size; C.I. – upper and lower
limits of the 95% conﬁdence interval of the difference. Standard deviations are in parenthesis.
# Lower value indicates better performance.
* p < 0.05.
** p  0.01.
+ Medium effect size.
++ Large effect size.
Fig. 1. Activation of the neural network after intranasal administration. Neuro-electrophysiological activity changes at the end of the six-month
intervention as indicated by the graphical representation of the sLORETA paired t-statistics results. The experimental group demonstrated signiﬁcantly
elevated theta current density (shown in red) in the anterior cingulate cortex, inferior frontal cortex, dorsolateral prefrontal cortex, and pre-supplementary
motor area during the No-Go condition after the six-month intervention (max. t = 9.4, p < 0.05), whereas the control group did not show any signiﬁcant
change. (For interpretation of the references to color in text, the reader is referred to the web version of this article.)
A.S. Chan et al. / Research in Autism Spectrum Disorders 8 (2014) 681–6916863.2. Intranasal herbal medicine enhanced prefrontal and anterior cingulate cortices activity
The neural mechanism underlying the enhancement in executive control of behaviors was examined by localizing EEG
theta source activities in the ROIs (IFC: BA10/47; DLPFC: BA9/46; pSMA: BA6; ACC: BA24/32) during a Go/No-Go task using
sLORETA voxel-by-voxel paired t statistics for each group. After six months of treatment, the experimental group showed
signiﬁcantly elevated theta current density power across all ROIs during the No-Go condition, t maximum = 9.4, p < 0.05
(lower image in Fig. 1). In contrast, the control group did not show a signiﬁcant change in current density at any coordinate
within the ROIs after six months, t maximum = 1.65, p > 0.05 (upper image in Fig. 1). Table 3 presents the corresponding
Table 3
Total amount and distribution of cortical voxels showing signiﬁcantly increased theta current density localized at the regions of interests of the control and
experimental groups at No-Go condition after six months.
Group Anatomical regions (abbreviation) Brodmann areas (BAs) No. of sig. voxels Max. t value
Left Right
Control Anterior Cingulate Cortex (ACC) 24 – – 0.00
32 – – 0.00
Inferior Frontal Cortex (IFC) 10 – – 0.72
47 – – 0.73
Dorsolateral Prefrontal Cortex (DLPFC) 9 – – 0.80
46 – – 0.62
Pre-supplementary Motor Area (pSMA) 6 – – 0.41
Experimental Anterior Cingulate Cortex (ACC) 24 8 10 4.79*
32 31 43 7.79*
Inferior Frontal Cortex (IFC) 10 57 134 9.29*
47 – 108 8.03*
Dorsolateral Prefrontal Cortex (DLPFC) 9 28 57 6.78*
46 – 21 6.84*
Pre-supplementary Motor Area (pSMA) 6 1 11 3.34*
Note. No. of sig. voxels: number of voxels at the left and the right hemisphere of the cortex with signiﬁcantly increased current density above the t threshold
value (*p < 0.05). Max. t value: the highest t value within a speciﬁc region of interest indicating the greatest signiﬁcant increase in current density power.
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experimental group, a total of 509 voxels within the ROIs showed above-threshold increments in the current density power
after intervention. An inspection of the distribution of signiﬁcant voxels in each hemisphere revealed that the ACC was more
bilaterally involved, and that the IFC, DLPFC, and pSMA were more right-lateralized. As revealed by the maximum t value, the
IFC (BA10/47) and ACC (BA32) showed the greatest pre-post difference. However, in the control group, there was no
signiﬁcant change in the current density power for any voxel within the ROIs.
The present results are consistent with our previous ﬁndings of a signiﬁcantly increased ACC current density after the
application of the herbal nasal drops (Chan et al., 2011a). Furthermore, the elevated current density in the IFC, DLPFC, and
sPMR, which coincided with the enhanced ACC current density, is consistent with the distributed functional network that
has been proposed to mediate response selection and inhibition (Chambers et al., 2009; Kiesel et al., 2010). Such a treatment-
speciﬁc alteration in neural oscillation within the anterior and medial brain regions provides a possible explanation for the
enhanced executive functions in the experimental group.
3.3. Intranasal herbal medicine improved daily executive behaviors
In light of the subjects’ positive changes in executive function test performance and EEG activity after herbal nasal
administration, it would be important to investigate whether the improvements observed under experimental conditions
could be generalized to everyday behaviors. Therefore, a further pre-post comparison was performed on the parents’
evaluations of their child’s executive behaviors in everyday life based on three standardized questionnaires.
While there was no between-group difference in parental ratings before the intervention, t range = 0.24 to 0.16, p > 0.05,
after the six-month intervention, parents of children in the experimental group, but not those in the control group, reported
fewer behavioral problems related to executive dysfunctions. Repeated measures ANOVAs showed a marginally signiﬁcant
group by time interaction effect on the Hyperactivity subscale of the CRS-R, F = 3.97, p = 0.06, and a signiﬁcant or marginally
signiﬁcant main effect of time on the Hyperactivity subscale of the CPRS, F = 7.55, p = 0.01, the Global Executive Composite
and Metacognition Index of the BRIEF, F = 3.14 and 4.04, p = 0.09 and 0.05, respectively. Post hoc paired t tests revealed that
the experimental group reported reduced behavioral problems related to overall executive functions, response inhibition
and ﬂexibility, and planning, t = 1.29–2.71, p = 0.01–0.03, with medium effect sizes (0.54–0.70) (Table 4). In contrast, the
control group did not show such improvements after six months, t = 0.56 to 1.12, p = 0.14–0.40, with small effect sizes
(0.07–0.30). The maximal extent of improvement in the experimental group was 39%, which is more than a double that of the
control group, 15%. These ﬁndings suggest that the therapeutic effect of the herbal nasal administration can be generalized to
daily executive behaviors, implying that the herbal nasal drops could be an intervention for executive dysfunction in ASD.
4. Discussion
The study revealed enhancements in both the experimental test results and the real-life behaviors related to executive
functions in children with ASD after the intranasal application of the herbal medicine for six months. Given that the control
group, which did not receive the herbal treatment, did not show as much improvement in executive functions, the positive
outcomes found in the experimental group could be attributed to the herbal nasal drops, rather than natural developmental
growth. The therapeutic effects of the herbal formula are consistent with our pilot data, which revealed a greater
improvement in some frontal lobe functions, including initiation and inhibition of speech and actions, and some pro-social
Table 4
Mean parental rating on children from the control and experimental groups before and after six months.
Cognitive domain/
measures
Control group (n = 15) p Value E.S. C.I. Experimental group (n = 15) p Value E.S. C.I.
Pre Post Pre Post
Overall executive functions
BRIEF-GEC 150.29 (18.78) 148.93 (18.67) 0.37 0.09 7.43 to 10.14 150.07 (34.03) 140.47 (29.80) 0.03* 0.54+ 0.30 to 19.50
Inhibition and ﬂexibility
BRIEF-BRI 53.07 (9.45) 52.57 (9.46) 0.40 0.07 3.76 to 4.76 52.33 (14.42) 49.00 (11.01) 0.11 0.33 2.19 to 8.86
CPRS-H 8.43 (4.78) 7.14 (5.25) 0.14 0.30 1.19 to 3.76 8.67 (6.18) 5.27 (3.26) 0.01** 0.70+ 0.71 to 6.09
CRS-R-H 9.33 (4.30) 10.07 (5.70) 0.29 0.14 3.57 to 2.10 9.67 (7.15) 7.00 (4.96) 0.01** 0.64+ 0.35 to 4.98
Planning and organization
BRIEF-MI 97.21 (14.31) 96.36 (13.62) 0.37 0.09 4.72 to 6.44 97.73 (21.61) 91.47 (19.91) 0.01** 0.66+ 1.05 to 11.48
Note. BRIEF-GEC: Global Executive Composite of the Behavior Rating Inventory of Executive Function; BRIEF-MI: Metacognition Index of the BRIEF; BRIEF-
BRI: Behavioral Regulation Index of the BRIEF; CPRS-H: Hyperactivity Subscale of the Children’s Psychiatric Rating Scale; CRS-R-H: Hyperactivity Subscale of
the Conners’ Rating Scale-Revised. E.S.: effect size; C.I.: upper and lower limits of the 95% conﬁdence interval of the difference. Standard deviations are in
parenthesis. Lower value indicates less severe problems.
* p < 0.05.
** p  0.01.
+ Medium effect size.
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publication). Although the speciﬁc mechanism for the herbal formula’s effectiveness remains unknown, it could be related to
the medical principle underlying the development of the herbal formula. The formula was developed using a basic principle,
‘‘healing by opening the bodily oriﬁces,’’ of the traditional Shaolin Chan-based medicine, namely Dejian Mind–Body
Intervention (DMBI). In the DMBI model, the intranasal application of the herbal formula is one of the methods to open the
oriﬁces, while diet modiﬁcation and practicing Nei Gong (a form of mind–body exercise) are the others (can refer to Chan,
2010, 2013 for more details). Because they are governed by the same principle, treatments applying the other methods have
shown similar positive outcomes (Chan, Sze, & Shi, 2008; Chan, Sze, Cheung, Lam, & Shi, 2009; Chan, Cheung, Sze, Leung, &
Shi, 2011b; Chan, Cheung, Tsui, Sze, & Shi, 2011c; Chan, Sze, Cheung, Han, & Leung, 2011e; Chan, Sze, Han, & Cheung, 2012a;
Chan et al., 2012b, 2012c; Chan, Han, Sze, Wong, & Cheung, 2013; Chan, Sze, Siu, Lau, & Cheung, 2013; Chan, Han, & Cheung,
2014; Chan, Sze, Woo, & Yu, 2014; Yu, Woo, Chan, & Sze, in press). However, the extent of improvement in the present study
using herbal nasal drops is greater than those observed in the studies using other methods. Speciﬁcally, the present results
showed a consistent 40–68% enhancement in inhibition, ﬂexibility, and planning, whereas the previous ﬁndings showed a
17–42% improvement on the same test measures (Chan et al., 2012a, 2013b). Such a greater degree of treatment efﬁcacy in
the present study could be due to a longer treatment period (i.e., six months vs. one to two months), and/or the speciﬁc
robust effect of the herbal nasal drops that have the capacity to trigger neurophysiological alterations through the direct
nose–brain pathway.
Another important ﬁnding was the treatment-speciﬁc alteration in electrophysiological activity of a neural network that
mediates the executive control of behaviors. The present study replicated the immediate effect of intranasal application of
the herbal nasal drops that was observed previously in a group of normal adults, speciﬁcally an increase in EEG theta
oscillation localized to the ACC and theta cordance (an index correlated with cerebral perfusion) in the frontal brain region
(Chan et al., 2011a). It should be noted that the extent of elevation in brain activity in the present study is much greater than
that observed in a previous study on normal individuals, e.g., the maximum t values in ACC activity were 2–3 times higher in
the present study (t = 4.79 and 7.79) compared to those in the previous study (t = 2.65). The greater effect in the present study
is reasonable because it involves patients with ASD (who are known to have functional abnormalities in ACC, and hence
greater room for enhancement) and a longer treatment duration (i.e., six months compared to the single dose in the previous
study). Cumulative empirical evidence has suggested that suppressed activity in the prefrontal and/or anterior cingulate
cortices in individuals with ASD is associated with an impairment of the executive functions that manifests in daily life,
including emotional processing, inhibitory control, and stimulus-response monitoring (Chan et al., 2011d; Kana et al., 2007;
Philip et al., 2012). Particularly, the IFC in the right hemisphere has been suggested to be a key region for response inhibition
in normal individuals (Aron, Robbins, & Poldrack, 2004) and has repeatedly been reported to show abnormal activation and
reduced functional connectivity with other inhibition-related brain regions in the ASD population (Kana et al., 2007; Lee
et al., 2009). In our present study, children who applied the herbal nasal drops demonstrated the greatest degree of post-
intervention elevation in the current density at the right IFC. The greatest degree of change in the IFC is reﬂected by the
highest t value which indicates the most signiﬁcant pre-post difference and a three to four times greater number of voxels
with signiﬁcant differences at the IFC, compared to the results obtained for the ACC, DLPFC and sPMR. The present ﬁndings
suggest the possibility of applying the herbal nasal drops as a complementary treatment for patients with functional
abnormalities in the PFC and ACC.
The potential beneﬁts of the herbal nasal drops are consistent with the treatment effects of some conventional behavioral
interventions and with oxytocin treatment for enhancing executive functions and related behavioral and emotional
problems in ASD (Andari et al., 2010; Guastella et al., 2010; Ospina et al., 2008; Vismara & Rogers, 2010). In view of the
limited therapeutic effects of conventional behavioral therapy for low-functioning children and that of oxytocin (previous
A.S. Chan et al. / Research in Autism Spectrum Disorders 8 (2014) 681–691 689studies have reported a performance improvement of approximately 10%), the effects of the herbal nasal drops for children
with ASD reported in this study may shed some light on the possibility of applying the nasal drops as a complementary
intervention for individuals with ASD, speciﬁcally those with limited intelligence or more severe autistic symptoms.
Despite the encouraging results of the present study, the sample size is relatively small. Further studies with larger
sample size are warranted to investigate whether the magnitude of the therapeutic effects of the herbal nasal drops can be
replicated. Additionally, it is worth conducting randomized controlled trials on the herbal formula with placebo treatment as
a control to rule out a possible placebo effect underlying the positive treatment outcomes. Given that executive function
deﬁcits are common in patients with various brain disorders (e.g., attention-deﬁcit/hyperactivity disorder, traumatic brain
injury, dementia), it may be worthwhile to extend our investigation of this intervention to other clinical populations. In light
of our clinical observations and pilot data on the potential beneﬁts of the herbal nasal drops to children with more severe
autistic symptoms and/or mental retardation, a treatment study with those speciﬁc populations with larger samples will
also be considered.
5. Conclusion
This study provides support for the long-term therapeutic effects of a patented herbal formula on a wide range of
executive functions that are measured by neuropsychological tests and daily behavioral checklists, which are in line with the
increased current density power in the ACC and PFC. Such encouraging ﬁndings provide added support for the effectiveness
of the herbal formula for ASD and shed some light on its potential clinical applicability for improving executive functions and
altering the neural processing patterns of people suffering from frontal lobe dysfunctions.
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